Cardiovascular disease continues to be a dominant cause of morbidity and mortality in the United States and throughout much of the world. Advances that have been made in recent decades have come from the dedication and talents of many researchers working at the basic science level up through to clinical translation including population and care delivery studies. Over the past 35 years, The Johns Hopkins T32 Program in Cardiovascular Disease has trained many of these researchers, and with this renewal proposal we aim to continue this success. Our philosophy is to provide a broad-based, multi- and inter-disciplinary research environment with which to train post-doctoral fellows in basic, translational, clinical, and/or population science. Our program accepts physicians in Cardiology, some with PhDs as well, who are dedicated to pursuing an academic research career, and non-clinical fellows (PhD or MD) who are pursuing cardiovascular research. This mixture of basic and clinical scientists has fostered an unusual environment conducive to out-of-the-box thinking and translation of novel approaches to new understandings and treatment of cardiovascular disease. Most mentors have their primary appointments in the Division of Cardiology, but our faculty also include members from Pulmonary Medicine, Radiology, Institutes of Genetic Medicine and Cell Engineering, Biomedical Engineering, Pediatric Cardiology, Pathology, Epidemiology, and The Welch Center of Clinical Research. All of the faculty have long- standing histories of collaborations. Ten primary areas of research are covered: basic science in ventricular and vascular pathobiology, molecular biology and genetics, proteomics, cardiovascular imaging and computational modeling, epidemiology, risk assessment, genome-wide association research, preventive medicine strategies, clinical/translational studies in electrophysiology, coronary disease, and heart failure, and cardiovascular aging. The program supports 12 positions (our last renewal was approved for 13 positions) for 2 years of un-interrupted research training. It also includes a position with a 3rd structured year of formal course work to provide a masters degree in clinical investigation. With this renewal, we continue our primary goal of providing leadership in academic cardiology, training future leaders in all levels of research to help combat cardiovascular disease.

Public Health Relevance

Heart and vascular disease is a leading cause of disability and death in the United States. The Johns Hopkins Cardiology Post-doctoral Training Program, now in its 35th consecutive year, provides broad multi-disciplinary training spanning from basic science up through to population/outcomes research. Our goal is to train the next generation of academic cardiovascular research leaders to continue the important work of tackling these important and common diseases.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Carlson, Drew E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Blice-Baum, Anna C; Zambon, Alexander C; Kaushik, Gaurav et al. (2017) Modest overexpression of FOXO maintains cardiac proteostasis and ameliorates age-associated functional decline. Aging Cell 16:93-103
Aronis, Konstantinos N; Berger, Ronald D; Ashikaga, Hiroshi (2017) Rotors: How Do We Know When They Are Real? Circ Arrhythm Electrophysiol 10:
Blaha, Michael J; Whelton, Seamus P; Al Rifai, Mahmoud et al. (2017) Rationale and design of the coronary artery calcium consortium: A multicenter cohort study. J Cardiovasc Comput Tomogr 11:54-61
Metkus, Thomas S; Albaeni, Aiham; Chandra-Strobos, Nisha et al. (2017) Incidence and Prognostic Impact of Respiratory Support in Patients With ST-Segment Elevation Myocardial Infarction. Am J Cardiol 119:171-177
Houston, Brian A; Schneider, Andrea L C; Vaishnav, Joban et al. (2017) Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant 36:380-385
Tereshchenko, Larisa G; Feeny, Albert; Shelton, Erica et al. (2017) Dynamic Changes in High-Sensitivity Cardiac Troponin I Are Associated with Dynamic Changes in Sum Absolute QRST Integral on Surface Electrocardiogram in Acute Decompensated Heart Failure. Ann Noninvasive Electrocardiol 22:
Kim, Grace E; Kass, David A (2017) Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease. Handb Exp Pharmacol 243:249-269
Leucker, Thorsten M; Valenta, Ines; Schindler, Thomas Hellmut (2017) Positron Emission Tomography-Determined Hyperemic Flow, Myocardial Flow Reserve, and Flow Gradient-Quo Vadis? Front Cardiovasc Med 4:46
Metkus, Thomas S; Guallar, Eliseo; Sokoll, Lori et al. (2017) Prevalence and Prognostic Association of Circulating Troponin in the Acute Respiratory Distress Syndrome. Crit Care Med 45:1709-1717
Whelton, Seamus P; Blumenthal, Roger S (2017) Beyond the Headlines: Insights on Potassium Supplementation for the Treatment of Hypertension From the Canadian Hypertension Education Program Guidelines (CHEP). Circulation 135:3-4

Showing the most recent 10 out of 170 publications